Integer (NYSE:ITGR) Stock Rating Upgraded by Wall Street Zen

Integer (NYSE:ITGR) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other equities research analysts also recently commented on the stock. Truist Financial lifted their target price on shares of Integer from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Citigroup upped their price objective on Integer from $69.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of Integer in a report on Monday, December 29th. Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 target price (down from $132.00) on shares of Integer in a research report on Friday, October 24th. Finally, KeyCorp cut their price target on Integer from $145.00 to $133.00 and set an “overweight” rating for the company in a research note on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $98.38.

Integer Price Performance

Shares of NYSE:ITGR opened at $85.78 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.45 and a current ratio of 3.71. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of 35.89, a price-to-earnings-growth ratio of 0.79 and a beta of 0.78. The business has a 50-day simple moving average of $74.96 and a two-hundred day simple moving average of $92.86. Integer has a fifty-two week low of $62.00 and a fifty-two week high of $146.36.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.11. Integer had a net margin of 4.75% and a return on equity of 12.84%. During the same quarter in the prior year, the firm posted $1.43 EPS. The business’s revenue was up 8.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, analysts expect that Integer will post 6.01 earnings per share for the current year.

Integer announced that its Board of Directors has approved a share repurchase program on Tuesday, November 4th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 8.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, CEO Payman Khales acquired 3,127 shares of the stock in a transaction dated Thursday, October 30th. The shares were purchased at an average cost of $64.94 per share, with a total value of $203,067.38. Following the transaction, the chief executive officer directly owned 22,865 shares in the company, valued at approximately $1,484,853.10. This represents a 15.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Cheryl C. Capps bought 1,600 shares of Integer stock in a transaction that occurred on Thursday, November 6th. The stock was purchased at an average cost of $66.70 per share, with a total value of $106,720.00. Following the completion of the acquisition, the director directly owned 11,702 shares in the company, valued at $780,523.40. This represents a 15.84% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 5,843 shares of company stock valued at $384,771 in the last 90 days. Corporate insiders own 2.16% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Salomon & Ludwin LLC purchased a new stake in Integer during the 3rd quarter valued at approximately $26,000. Global Retirement Partners LLC boosted its position in shares of Integer by 293.8% during the third quarter. Global Retirement Partners LLC now owns 319 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 238 shares during the last quarter. CWM LLC grew its stake in Integer by 46.1% during the second quarter. CWM LLC now owns 355 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 112 shares in the last quarter. MAI Capital Management increased its holdings in Integer by 220.9% in the 2nd quarter. MAI Capital Management now owns 369 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 254 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Integer by 210.5% in the second quarter. EverSource Wealth Advisors LLC now owns 534 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 362 shares in the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer News Summary

Here are the key news stories impacting Integer this week:

• Negative Sentiment: Multiple firms (Rosen Law Firm) reminded shareholders of a lead‑plaintiff deadline of February 9, 2026 for a securities class action covering purchases between July 25, 2024 and October 22, 2025; investors are being urged to contact counsel. Read More.
• Negative Sentiment: Bleichmar Fonti & Auld (BFA) and related filings notify investors that a class action was filed alleging securities fraud after a significant stock drop; the notice urges affected investors to seek information about potential claims. Read More.
• Negative Sentiment: Kuehn Law states it is investigating whether Integer and certain officers overstated competitive position and long‑term growth from two EP devices, and whether sales deterioration was concealed — specific allegations that amplify potential liability exposure. Read More.
• Negative Sentiment: Levi & Korsinsky, Berger Montague, Bragar Eagel & Squire and other plaintiff firms have issued separate notices seeking clients and reminding investors of the same Feb. 9 deadline — a coordinated wave of filings that increases the probability of consolidated, high‑stakes litigation. Read More.
• Negative Sentiment: Additional national firms (Pomerantz, Glancy Prongay & Murray, The Gross Law Firm, ClaimsFiler, Bronstein, etc.) have published investor alerts and filing reminders — reinforcing market focus on litigation risk and the potential for discovery, damages and settlement costs. Read More.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.